GIP-Gip2019ces-1UP 1..179
CANCERS OF THE ESOPHAGUS AND STOMACH 2 Oral Abstract Session, Thu, 2:15 PM-3:45 PM and Poster Session (Board #D12), Thu, 11:30 AM-1:00 PM and 5:30 PM-6:30 PM Pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer: Phase III KEYNOTE-181 study. Takashi Kojima, Kei Muro, Eric Francois, Chih-Hung Hsu, Toshikazu Moriwaki, Sung-Bae Kim, Se-Hoon Lee, Jaafar Bennouna, Ken Kato, Shen Lin, Shi-Qui Qin, Paula Ferreira, Toshihiko Doi, Antoine Adenis, Peter C. Enzinger, Manish A. Shah, Ruixue Wang, Pooja Bhagia, S. Peter Kang, Jean-Philippe Metges; Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan; Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan; Lacassagne Anticancer Center, Nice, France; National Taiwan University Hospital, Taipei, Taiwan; University of Tsukuba, Tsukuba, Japan; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea; Division of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea; University Hospital of Nantes, Nantes, France; Division of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan; Beijing Cancer Hospital, Beijing, China; PLA Cancer Centre of Nanjing Bayi Hospital, Nanjing, China; Instituto Portuguesˆ de Oncologia Porto, Porto, Portugal; National Cancer Center Hospital East, Chiba, Japan; Centre Oscar Lambret, Lille, France; Dana-Farber Cancer Institute, Boston, MA; Weill Cornell Medicine/ New York Presbyterian Hospital, New York, NY; MSD China, Beijing, China; Merck, Kenilworth, NJ; Merck & Co., Inc., Kenilworth, NJ; Oncology & Haematology Institute, Brest University Hospital, Brest, France Background: Patients with advanced esophageal cancer after first-line chemotherapy (chemo) have a poor prognosis and limited treatment options.
[Show full text]